ages 20-34, and by 27.7% and 46.0% for patients ages 35-49 years by 2030. 5 The loss of loved ones to early onset CRC has spurred advocacy supporting CRC screening and research. 6 Initial studies of young-onset CRC focused on treatment patterns, genetics, and outcomes, noting a propensity to treat this population more aggressively, and reporting inconsistent results on disease-specific survival. 4, [7] [8] [9] It has been postulated that this population tends to present late with respect to symptom development, which may explain the more advanced stage distribution observed at diagnosis. 5, 10 Sporadic mutations in young persons may cause more biologically aggressive tumor phenotypes, with hereditary CRC syndromes only accounting for approximately 15% of young-onset CRCs. [11] [12] [13] [14] [15] [16] [17] Some studies have explored features of CRC presentation in younger patients, [18] [19] [20] [21] including the potential influence of health insurance 10 and racial background. 22 It is unclear whether more timely presentation by patients or more expeditious work-up by physicians could improve the outcomes of young persons with CRC. This study highlights the patient perspective from initial symptom onset to diagnosis to identify factors affecting timely management and stage at diagnosis. We undertook a single-institution cohort study to examine the type and duration of presenting symptoms and time to diagnosis in younger versus older patients with CRC, and identify factors associated with time to diagnosis and stage at diagnosis. We hypothesized that symptom duration and work-up period would be longer in our younger cohort, and that these longer periods would be associated with more advanced stage at diagnosis.
Methods

Study Design, Data Sources, and Study Cohort
The Stanford University Institutional Review Board approved this study. We used the Stanford Cancer Institute Research Database (http://med.stanford.edu/ biostatistics/dcc/sccrdb.html) to identify all patients with a diagnosis of colorectal adenocarcinoma, confirmed by Stanford pathologists, who were seen at the Stanford Cancer Institute between January 1, 2008, and December 31, 2014, including patients referred from inside or outside Stanford's primary care network. We excluded patients with adenocarcinoma in situ, appendiceal cancer, or recurrent cancer.
We conducted a retrospective chart review of all patients <50 years of age at time of CRC diagnosis (young-onset), and of a random sample of a comparable number of patients 50 years of age at time of diagnosis who were not diagnosed with CRC as a result of age-appropriate screening.
We extracted initial symptoms, symptom duration, setting, date of first medical visit, family history, history of inflammatory bowel disease (IBD), and number of subsequent clinic visits before diagnosis. 
Outcomes and Definitions
Our primary outcome was time to diagnosis, which was defined as the sum of symptom duration and workup duration. Symptom duration was defined as the patient's self-reported length of chief presenting symptom at the time of initial visit, as documented in the clinical record. For the patients who were identified incidentally (eg, anemia or abnormal imaging), symptom duration was set to zero days. Work-up duration was defined as the number of days from first medical visit to date of pathologic diagnosis.
Our secondary outcomes were symptom duration, work-up duration, and stage at diagnosis. Possible CRC symptoms were defined as hematochezia, melena, abdominal pain, fatigue, weight loss, constipation, diarrhea, and other changes in bowel habits. Nonspecific symptoms were defined as nausea/emesis, bloating/gas, and other. Stages I and II were defined as non-advanced and stages III and IV as advanced.
Right-sided colon cancers were identified as sites involving the cecum, ascending colon, hepatic flexure, and transverse colon. Left-sided colon cancers were identified as sites involving the splenic flexure, descending colon, sigmoid colon, and rectosigmoid. Family history of CRC was defined as the presence of a first-degree, second-degree, and/or third-degree relative with CRC.
Patients with suspected hereditary cancer syndromes based on abnormal tumor immunohistochemistry or clinical impression were classified as "confirmed," "probable," "possible" or "Lynch Syndrome excluded" as defined and shown in Table 1 .
Statistical Analysis
We compared demographic and clinical features between younger and older patients using chi-square tests (or Fisher's exact test for variables with small counts) for categorical variables. For time to diagnosis, symptom, and work-up duration, we calculated medians and interquartile ranges (IQR), and compared distributions by age group using the Wilcoxon rank sum test. Spearman correlation coefficient was used to estimate the correlation between symptom and work-up duration. We compared the proportion of hematochezia and abdominal pain by cancer site and age group using the Cochran-MantelHaenszel test. We conducted univariable analyses, using the Wilcoxon rank sum test, for time to diagnosis for each variable listed below, separately for each age group, to determine if there was an association between time to diagnosis and the variable for each age group. Our primary objective was to assess if there was a significant difference in time to diagnosis between younger and older patients. We fit a linear regression model using log-transformed time to diagnosis as the outcome, and age group, sex, ethnicity, family history of CRC, diagnosis of confirmed or probable genetic syndrome, IBD, setting of first medical visit, and symptom type (CRC, nonspecific, incidental discovery) as predictors. For our secondary outcomes of symptom duration and work-up duration, we fit a multivariate linear regression model using log-transformed symptom and work-up durations as the outcomes, and the variables listed previously as predictors. To enable ease of interpretation, we exponentiated the estimates of our models to present odds ratios and 95% confidence intervals.
We assessed if there was a differential association between time to diagnosis, symptom or work-up duration, and stage of disease (advanced or non-advanced) by age group. For time to diagnosis, we fit a linear regression model using log-transformed time to diagnosis as the outcome, and age group, stage of disease, and the interaction between age group and stage of disease as predictors. For symptom and work-up duration, we fit a multivariate linear regression model using a similar approach. For our secondary outcome of stage of disease, we ran a multinomial logit model 23 with stage of disease as the outcome, and age group, sex, family history of CRC, diagnosis of confirmed or probable genetic syndrome, IBD, setting of first medical visit, and symptom type as predictors.
All statistical tests were 2-tailed using a significance level of 0.05. Analyses were performed in SAS 9.4 (SAS Institute Inc, Cary, NC).
Results
Cohort Demographics and Clinical Features
We identified 1759 patients (382 patients age <50 years and 1377 patients age 50 years) with colorectal tumors from the Stanford Cancer Institute Research Database (Figure 1 ). After review of records and application of exclusion criteria (Figure 1 ), our analytic cohort consisted of 253 patients age <50 years and 232 patients age 50 years.
Younger and older patients were similar with respect to sex, race/ethnicity, marital status, body mass index, cancer site, and pre-existing IBD (Table 1) . Younger patients were more likely than older patients to have advanced stage at diagnosis (72% vs 63%; P ¼ .03), any family history of CRC (25% vs 17%; P ¼ .03), and confirmed or probable hereditary cancer syndromes (7% vs 1%; P < .01) ( Table 1) . Younger patients were more likely than older patients to have rectal cancer (40% vs 35%), but the difference did not reach statistical significance (P ¼ .29). Colon cancer site differed by age (P ¼ .01); younger patients were more likely to have left-sided colon cancer (41% vs 34%) and older patients were more likely to have right-sided colon cancer (29% vs 16%) ( Table 1) . Most patients were first seen by a primary care provider (Table 2 ). On average, younger patients had 27% more visits than older patients until diagnosis after initial primary care provider visit (P ¼ .05) (Supplementary Table 1 ). Most patients presented with 1 symptom but approximately one-third presented with 2 symptoms (Table 2 ). The chief presenting symptom type (CRC, nonspecific, incidental discovery) differed by age group (P ¼ .04); more patients in the older age group were discovered through an incidental finding (10% vs 5%). In both age groups, the most common chief presenting symptom was hematochezia in rectal cancer, and abdominal pain in colon cancer; there was a strong association between symptom and cancer site after adjusting for age group (Cochran-Mantel-Haenszel test P < .01) ( Table 2) .
Time to Diagnosis, Symptom Duration, and Work-Up Duration Table 3) . Symptom and work-up durations were also skewed (Supplementary Figure 2) . Symptom and work-up duration were slightly correlated overall (Spearman correlation coefficient r ¼ .24; P < .01); but a significant correlation was not observed within groups (<50 years: r ¼ .07, P ¼ .27; 50 years: r ¼ .12, P ¼ .07) (Supplementary Figure 2) . Symptom durations were longer than work-up durations, and both were significantly longer in patients with youngonset CRC (Table 3) .
Predictors of Time to Diagnosis
In univariable analyses within each age group, time to diagnosis was not significantly associated with sex, family history, confirmed or probable hereditary cancer syndromes, or pre-existing IBD, but it was significantly associated with symptom type (P < .01) and provider seen at first medical visit (P < .01 for <50 years; P ¼ .02 for 50 years). Among patients <50 years, median (IQR) days to diagnosis were 144 (89-275) when first seen by a primary care provider, 66 (24-194) when first seen in the emergency department visit, and 48 (18-228) when first seen by a specialist. Among patients 50 years, the respective days were 113 (46-210), 28 (6-121), and 63 (18-155).
In multivariable analyses, age group, type of medical provider seen at first visit, and symptom type (CRC vs nonspecific symptoms) were significantly associated with time to diagnosis (Table 4 ). Time to diagnosis was 1.4-fold longer in patients <50 years old compared with patients 50 years old (P < .01).
Association Between Time to Diagnosis and Stage at Diagnosis
The longest time to diagnosis was observed among patients <50 years old with non-advanced CRC at diagnosis (stages I and II) followed by patients <50 years old with advanced CRC at diagnosis (stages III and IV) (median days, 174 vs 124) (Figure 2 ). Both symptom duration and work-up duration were shorter in those with advanced CRC compared with those with nonadvanced CRC in the young-onset cohort (Figure 2) . The association between symptom and work-up duration by age group was not significantly different by stage at diagnosis (interaction P value ¼ .54).
Predictors of Stage of Disease at Diagnosis
In multivariable analysis examining stage of disease, only age group was significantly associated with stage at diagnosis (P ¼ .03) (Supplementary Table 2 ). Younger patients with confirmed or probable Lynch Syndrome tended to present with less advanced disease (Supplementary Table 3 ).
Discussion
This study addresses timely questions related to CRC in younger patients. It explores in detail presenting symptoms, clinical features, time to diagnosis, and stage at diagnosis in a relatively large single-institution cohort.
Prior research has not traced in detail young patients' longitudinal experience from initial symptoms to first medical visit to CRC diagnosis. Two prior smaller studies examined time to diagnosis but did not capture work-up period. 18, 19 A larger retrospective study did not include an older comparison group or quantify time to diagnosis. A separate study evaluated CRC patients younger than age 65, but not specifically patients younger than age 50. 24 Our cohort's demographics reflect a typical academic cancer center, with an overall high proportion of patients with advanced cancer, and rectal cancer, which requires a multidisciplinary approach. Our results are consistent with previous reports of more advanced disease at time of diagnosis, and of a higher proportion of left-sided disease in younger patients. 4, 9, 10, 25 The mean age at diagnosis in our group of patients younger than 50 (41 years) was comparable with that reported in a recent study using Surveillance, Epidemiology, and End Results data (42.5 years). 4 Our cohort is diverse, including representation of Hispanic (13%) and Asian (21%) patients, but includes few (2%) African-American patients.
In our study, 41% of the younger cohort presented with hematochezia as the chief presenting symptom, consistent with prior reports ranging from 26% to 51%. 18, 19 Most younger and older patients (90% and 82%, respectively) presented with colorectal symptoms. However, these symptoms are not specific for neoplasia, and challenges remain in defining appropriate and timely work-up. Patients with rectal cancer were more likely to present with hematochezia, whereas those with colon cancer were more likely to present with abdominal pain. In the appropriate context, it may be reasonable to consider a flexible sigmoidoscopy in younger patients with persistent hematochezia, particularly in resource-limited settings.
Our results confirm our first hypothesis that patients with young-onset CRC experience significantly longer symptom duration, longer work-up duration, and thus longer total time to diagnosis. In our study, younger patients also had more advanced stage at diagnosis. Both symptom duration before seeking care and time from presentation to diagnosis are potentially modifiable.
However, contrary to our second hypothesis, younger patients with stage III or IV disease had shorter symptom and work-up periods than those with stage I or II disease, suggesting that advanced stage at diagnosis is not explained simply by longer time to diagnosis. Nonetheless, it remains possible that more timely presentation by patients or more expeditious work-up by clinicians could improve outcomes for young patients with CRC. A previous study found that in patients with possible CRC symptoms, work-up duration <5 weeks was associated with decreased mortality. 26 The overall mean total time to diagnosis was 200 days, longer than the range of 54-156 days reported in previous studies. 18, 19 By age group, the periods that we observed were longer than those reported in Israel by Ben-Ishay et al, 18 who also found that time to diagnosis was longer in younger patients. Our study extends the observations in prior studies [18] [19] [20] by also capturing work-up duration to highlight the clinician's role in time to diagnosis.
Our finding that advanced stage at diagnosis does not seem to be explained simply by longer time to diagnosis suggests that biologic factors may be important determinants of stage at diagnosis. Although we could not ascertain with confidence the symptom severity at presentation, it is possible that more severe symptoms in patients with more advanced disease could have led to more expeditious work-up. It has been suggested that malignancies in young adults display a distinct biology. 27 Outcomes are affected by underlying biology and genetics. 25, [28] [29] [30] In a cohort of older patients from a single VA hospital, lagtime between referral for colonoscopy and diagnosis of CRC was inversely associated with mortality risk; this was likely related to the fact that patients with symptoms or abnormal labs or imaging studies had the shortest lagtime and presented with more advanced stage disease. 31 Our findings suggest that greater patient and clinician awareness of CRC symptoms may not be enough to overcome underlying biologic factors. Nonetheless, greater awareness of the rising incidence of young-onset CRC is warranted.
As might be expected, younger patients were more likely to have a family history of CRC, or a confirmed or probable diagnosis of a hereditary cancer syndrome, but confirmation of a genetic syndrome was rare, and in almost all cases it followed the diagnosis of CRC in the young patient. Few young patients with CRC had IBD. Thus, most young patients in our study did not have an identified indication for early screening. Having a first-degree relative with CRC approximately doubles a patient's risk of developing CRC. 32 The Family History Task Group of the National Supplementary Figure 2 . Distribution of log symptom duration and log work-up duration. Scatterplot with log symptom duration on x-axis and log work-up duration on y-axis. Nonadvanced stage (stage I or II) cases are shown in dark diamonds and advanced stage (stage III or IV) cases are shown in gray squares. Spearman correlation coefficient for <50 years age group for symptom duration and work-up duration ¼ 0.07, P ¼ .27; for 50 years age group 0.12, P ¼ .07.
Supplementary Figure 1 . Distribution of log total time to diagnosis by age group. Depicted as box and whisker plot in log days; shows right-skew distribution of data. 
